/
Hematology
Thalassemia
30
Pipeline Programs↗
44
Active Trials↗
26
Companies Involved↗
Thalassemia is an emerging landscape with 30 programs across 26 companies. The most active players are Kind Pharmaceuticals LLC, Agios Pharmaceuticals, Inc.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical14
Phase 12
Phase 210
Phase 34
Approved
No programs
Analysis
Modality Breakdown
85%
Small molecule
22 of 26 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 26 classified programs, each share of the total. Modality classified for 100% of 30 pipeline programs.
Analysis
Trial Status
150
clinical trials
Completed72 · 48%
Recruiting23 · 15%
Unknown status22 · 15%
Active, not recruiting13 · 9%
Terminated8 · 5%
Not yet recruiting6 · 4%
Other6 · 4%
Clinical Trials
Trial Activity
150 trials
Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT03937817·300 enrolled
Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients
Recruiting·—·Phase 1·NCT05745532·10 enrolled
the Safety and Efficacy Evaluation of HGI-002 Injection in Patients With Transfusion-Dependent α-Thalassemia
Recruiting·—·Phase 1·NCT05851105·3 enrolled
the Safety and Efficacy Evaluation of HGI-001 Injection in Patients With Transfusion-Dependent β-Thalassemia
Recruiting·—·Phase 1·NCT05864170·3 enrolled
Page 1 of 10
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)